NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

Your explanation is correct other than "OS is not the "gold standard""

Overall survival (OS) is the gold standard to assess novel therapeutics to treat cancer. However, to identify early efficacy and speed up drug approval, trials have used progression-free survival (PFS) as a surrogate endpoint (SE). Herein, we aimed to examine if PFS could function as an OS surrogate in advanced Esophageal Squamous Cell Carcinoma (ESCC) treated with first-line immunochemotherapy.

https://bmccancer.biomedcentral.com/articles/10.1186/s12885-023-10613-y#:~:text=Overall%20survival%20(OS)%20is%20the,a%20surrogate%20endpoint%20(SE).